About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of Nivolumab for Advanced Cancers in India

NCT03444766·9 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy OR advanced renal cell carcinoma (RCC) after prior therapy
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization

You may not be if

Participants with untreated, symptomatic central nervous system (CNS) metastases
Participants with carcinomatous meningitis
Participants with active, known or suspected autoimmune disease
Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
Other active malignancy requiring concurrent intervention

The record

StatusCompleted

PhasePhase 4

Taking part100

StartedMar 2018

UpdatedDec 4, 2020

Conditions

Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung Carcinoma Nonsmall Cell Lung Cancer Kidney Cancer Kidney Neoplasms+2

Where9

Local Institution
Bangalore, India
Local Institution
Bangalore, India
Local Institution
Bengaluru, India

Clareo Health | Study of Nivolumab for Advanced Cancers in India